Randomized controlled trial of Effectiveness And Safety By Using Attes Chi-Water Water To The CKD 2 - 4 Stages Patients (With Spleen And Kidney Deficiency, Complexity of Stasis And Turbidity)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003880

Enrollment

Unknown

Registered

2013-11-24

Start date

2014-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease (CKD)

Interventions

experimental groups:Attes Chi-Water Water

controlled groups:nothing

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. People suffering from chronic renal failure and being diagnosed to be in clinical CKD stage 2 ~ 4 (renal failure, 89 ml/min/1.73m2 = GFR = 15ml/min/1.73m2); 2. TCM diagnoses to have spleen and kidney deficiency, blood stasis and turbidity complexity problem; 3. Aged 18 to 65 years old, male or female; 4. Vuluntory to participate in this clinical study and signed consent letter; 5. With no record of participating in other clinical experimental project within the past month; 6. Without the use of ACEI, ARB class of drugs or having taken ACEI, ARB class of drugs for more than two months.

Exclusion criteria

Exclusion criteria: 1. Allergic to the attes chi-water or having other allergy problem; 2. Used to undergo or is currently under dialysis treatment; 3. Under the use of ACEI, ARB class of drugs less than two months, or the portion of dose not stable yet; 4. With severe heart disease (chronic heart failure, New York grading criteria: cardiac functional grading above 3), chronic lung disease, severe liver disease (AST, ALT twice higher than the range of normal value) and hematopoietic system (except for renal anemia) and other serious diseases, mental illness patients; 5. To associate with severe infections, acidosis (CO2CP = 15mmol / L) or to have higher serum potassium than normal people; 6. High risk hypertension patients (patients taking three appropriate antihypertensive drugs including diuretics but the blood pressure still greater than 140/90mmHg); 7. Nephrotic syndrome, lupus nephritis, renal and diabetic nephropathy and other active kidney disease; 8. Women that are pregnant or breastfeeding, or plan to be pregnant; 9. The researchers advised not appropriate to participate in the clinical experiments.

Design outcomes

Primary

Measure	Time frame
GF;	—

Secondary

Measure	Time frame
BUN;Scr;24h urine protein;CO2CP;electrolytes (P3 + / Ca2 +);uric acid;hemoglobin;serum total protein;serum albumin;24h urine volume;HEALTH SURVEY LIS;	—

Countries

China

Contacts

Public ContactLianbo Wei

TCM-Integrated of Southern Medical University

weilianbo@163.com+86 18664810831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026